New Drug Therapies Against Targeting Neurodegenerative Diseases: A Comprehensive Review

Simple item page
AudienciaPúblico en generales_ES
CoberturaMéxicoes_ES
Fecha de ingreso2026-09-15T00:29:41Z
Fecha de publicación2026-01-01
ResumenNeurodegenerative diseases encompass well-characterized behavioral, cognitive, and movement disorders that affect older people, impacting all facets of daily life. In Alzheimer's disease, specific antibodies targeting the β-amyloid protein (aducanumab, lecanemab, and others) are gaining special interest due to the approval of the first particular drugs against this disease. In Parkinson's disease, most drugs were approved several decades ago; however, new Phase II clinical trials point to monoclonal antibodies as a promising approach, and the report of alkaloids also suggests various therapeutic targets against this disease. Pick’s disease has a low prevalence; currently, no drugs are approved by government agencies. However, thanks to molecular tools, it has been possible to elucidate therapeutic targets implicated in the appearance of the disease. α-synuclein is the main therapeutic target in Lewy body disease; most of the reported molecules are in clinical Phases I and II. Additionally, drug repositioning may emerge as a viable option in the search for effective treatments against this disease. In amyotrophic lateral sclerosis, the appearance of newly approved drugs such as tofersen and edaravone, and some others in clinical Phase II (bosutinib), opens a new era in the understanding and treatment of this condition. Altered emotions and progressive damage in some brain regions characterize schizophrenia and vascular dementia. Combinations of tricyclic drugs are a trend that aims to increase the cognitive performance of patients with schizophrenia. In vascular dementia, numerous in vivo trials with molecules of different natures (flavonoids and lactones) have yielded positive results, delaying the progression of the disease. This review examines recent reports on molecules evaluated in vivo and in vitro models of the primary neurodegenerative diseases.es_ES
Doihttps://doi.org/10.2174/0118715249397580251117044621es_ES
URIhttps://riuat.uat.edu.mx/handle/123456789/1666
Idiomaeses_ES
EditorialBentham Science Publishers Ltd.es_ES
RelaciónCentral Nervous System Agents in Medicinal Chemistryes_ES
URL relacionadohttps://doi.org/10.2174/0118715249397580251117044621es_ES
DerechosAcceso abierto (Metadatos de producción científica)es_ES
Licenciahttp://purl.org/coar/access_right/c_abf2es_ES
FuenteCentral Nervous System Agents in Medicinal Chemistry
TítuloNew Drug Therapies Against Targeting Neurodegenerative Diseases: A Comprehensive Reviewes_ES
TipoArtículoes_ES
ArbitradoHa sido Arbitradoes_ES
AutorGonzález-Jiménez, Karen Alejandra
AutorHerrera-Mayorga, Elsa Verónica
AutorSánchez, Francisco Alejandro Paredes
AutorNiño-García, Nohemí
AutorTorres-Castillo, Jorge Ariel
AutorMartínez-Padrón, Hadassa Yuef
AutorSánchez-Sánchez, Mario
AutorGonzález-Jiménez, Karen Alejandraes_ES
AutorHerrera-Mayorga, Elsa Verónicaes_ES
AutorSánchez, Francisco Alejandro Paredeses_ES
AutorNiño-García, Nohemíes_ES
AutorTorres-Castillo, Jorge Arieles_ES
AutorMartínez-Padrón, Hadassa Yuefes_ES
AutorSánchez-Sánchez, Marioes_ES
InstituciónUniversidad Autónoma de Tamaulipas
InstituciónUniversidad Autónoma de Tamaulipases_ES
URL relacionadahttps://doi.org/10.2174/0118715249397580251117044621
Tipo de artículoIndexado
Tipo de artículoIndexadoes_ES
Volumen26es_ES

Files

Collections

Documentación Cientifica